JP2024532780A - Ｖｐｓ３４阻害剤を使用した併用療法 - Google Patents

Ｖｐｓ３４阻害剤を使用した併用療法 Download PDF

Info

Publication number
JP2024532780A
JP2024532780A JP2024508498A JP2024508498A JP2024532780A JP 2024532780 A JP2024532780 A JP 2024532780A JP 2024508498 A JP2024508498 A JP 2024508498A JP 2024508498 A JP2024508498 A JP 2024508498A JP 2024532780 A JP2024532780 A JP 2024532780A
Authority
JP
Japan
Prior art keywords
pyridin
alkyl
trifluoromethyl
pyridyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024508498A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023019259A5 (https=
JP2024532780A5 (https=
Inventor
ユー，ヤスミン
アンダーソン，マーティン
フリン，ダニエル・エル
ボグダン，マドゥミタ
Original Assignee
デシフェラ・ファーマシューティカルズ，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デシフェラ・ファーマシューティカルズ，エルエルシー filed Critical デシフェラ・ファーマシューティカルズ，エルエルシー
Publication of JP2024532780A publication Critical patent/JP2024532780A/ja
Publication of JPWO2023019259A5 publication Critical patent/JPWO2023019259A5/ja
Publication of JP2024532780A5 publication Critical patent/JP2024532780A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024508498A 2021-08-13 2022-08-12 Ｖｐｓ３４阻害剤を使用した併用療法 Pending JP2024532780A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163232983P 2021-08-13 2021-08-13
US63/232,983 2021-08-13
US202263317500P 2022-03-07 2022-03-07
US63/317,500 2022-03-07
PCT/US2022/074925 WO2023019259A1 (en) 2021-08-13 2022-08-12 Combination therapy of vps34 inhibitors and sting agonist for use in the treatment of cancer

Publications (3)

Publication Number Publication Date
JP2024532780A true JP2024532780A (ja) 2024-09-10
JPWO2023019259A5 JPWO2023019259A5 (https=) 2025-08-18
JP2024532780A5 JP2024532780A5 (https=) 2025-08-18

Family

ID=83188606

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024508498A Pending JP2024532780A (ja) 2021-08-13 2022-08-12 Ｖｐｓ３４阻害剤を使用した併用療法

Country Status (7)

Country Link
US (1) US20250127790A1 (https=)
EP (1) EP4384180A1 (https=)
JP (1) JP2024532780A (https=)
AU (1) AU2022326573A1 (https=)
CA (1) CA3228766A1 (https=)
TW (1) TW202320797A (https=)
WO (1) WO2023019259A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2630970A (en) * 2023-06-15 2024-12-18 Duke Street Bio Ltd PARP1 inhibitor compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015108881A1 (en) * 2014-01-14 2015-07-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
DK3416957T3 (da) 2016-02-19 2020-09-21 Sprint Bioscience Ab 6-heterocyclyl-4-morpholin-4-ylpyridin-2-on-forbindelser anvendelige ved behandlingen af cancer og diabetes
WO2019038387A1 (en) * 2017-08-23 2019-02-28 Sprint Bioscience Ab PYRIDYLPYRIDONE COMPOUNDS
CN111094271B (zh) * 2017-08-23 2023-02-28 思普瑞特生物科学公司 吡啶胺-吡啶酮化合物和嘧啶胺-吡啶酮化合物
WO2020008046A1 (en) * 2018-07-06 2020-01-09 Sprint Bioscience Ab Biomarker

Also Published As

Publication number Publication date
TW202320797A (zh) 2023-06-01
WO2023019259A1 (en) 2023-02-16
CA3228766A1 (en) 2023-02-16
EP4384180A1 (en) 2024-06-19
US20250127790A1 (en) 2025-04-24
AU2022326573A1 (en) 2024-02-15

Similar Documents

Publication Publication Date Title
TWI694076B (zh) 三唑并嘧啶化合物及其用途
US20230012463A1 (en) Cyclic sulfamide compounds and methods of using same
CN115667255B (zh) 卤代杂芳基和其他杂环激酶抑制剂及其用途
AU766081B2 (en) Phthalazine derivatives for treating inflammatory diseases
AU2012306746B2 (en) Benzonitrile derivatives as kinase inhibitors
JP2024063179A (ja) 癌関連障害の治療のためのアゾロピリミジン
RS64755B1 (sr) Heteroarilaminopirimidin amidni inhibitori autofagije i postupci njihove primene
US8859768B2 (en) Heteroaryls and uses thereof
TW201819386A (zh) Shp2磷酸酶抑制劑及其使用方法
JP2013522292A (ja) インダゾール化合物およびそれらの使用
EA029473B1 (ru) Применение ингибиторов pi3k для лечения острой и церебральной малярии
JP2008530216A (ja) Ｃｘｃｒ３アンタゴニスト活性を有する、複素環で置換された新規のピリジンまたはフェニル化合物
KR20130142153A (ko) 복소환 아민 및 이의 용도
EA024123B1 (ru) Тетрагидропиридопиримидиновые производные
TW202341982A (zh) Ｃｄｋ２抑制劑及其用途
WO2019224774A1 (en) Heterocyclic amides as rip1 kinase inhibitors
US11731943B2 (en) Therapeutic compounds, compositions and methods of use thereof
JP2024532780A (ja) Ｖｐｓ３４阻害剤を使用した併用療法
JP2021529806A (ja) 治療用複素環式化合物
US11926613B2 (en) Kinase inhibitors for the treatment of central and peripheral nervous system disorders
US12384773B2 (en) Thiazole compounds and methods of use thereof
TW202227428A (zh) 蛋白分泌抑制劑
US20260041669A1 (en) Solid forms of a cdk inhibitor
CN118201619A (zh) Vps34抑制剂与sting激动剂的组合疗法用于治疗癌症
TWI570116B (zh) 取代的吡唑酮化合物及其使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250807

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250807